Printer Friendly

In men with surgically resected stage I seminoma, a single dose of carboplatin chemotherapy is as effective as 2 to 3 weeks of radiation therapy in preventing recurrence and is much less toxic, according to study findings presented at the American Society of Clinical Oncology annual meeting in Chicago.

In men with surgically resected stage I seminoma, a single dose of carboplatin chemotherapy is as effective as 2 to 3 weeks of radiation therapy in preventing recurrence and is much less toxic, according to study findings presented at the American Society of Clinical Oncology annual meeting in Chicago. Testicular cancer is the most frequent cancer in men aged 15 to 45 years and surgery followed by radiation has been the standard of care, study leader Dr. Tim Oliver of St. Bartholomew's Hospital in London noted at the conference. "With this study, we fairly solidly confirmed" that single-dose carboplatin is an effective treatment in patients with early-stage seminoma, he added. In the study, 573 patients were randomized to a single dose of carboplatin given over 1 hour on an outpatient basis and 904 to a course of daily radiotherapy given over 2 or 3 weeks. At 5 years, the rate of relapse was similar in the two treatment arms--5% in the carboplatin arm and 4% in the radiation arm, Dr. Oliver reported. "Quite unexpectedly," Dr. Oliver reported, "we found that there was a 78% reduction--a hazard ratio of 0.22 and p value of 0.03--in the number of tumors in the remaining testicle," after a median follow up of 6.5 years.

Fifteen patients in the radiation arm developed contralateral testicular germ cell cancers versus 2 patients in the carboplatin arm. One patient in the radiation arm died of seminoma versus none in the chemotherapy arm. Adverse effects were low with both treatments, although patients treated with radiation reported higher levels of moderate to severe lethargy (24% vs. 7% for carboplatin) 4 weeks after starting treatment.
COPYRIGHT 2008 MedContent Media, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2008 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:RESEARCH & TECHNOLOGY
Publication:MondayMorning
Article Type:Brief article
Geographic Code:1USA
Date:Jun 9, 2008
Words:277
Previous Article:Among patients treated for stage III colon cancer, a family history of nonsyndromic colorectal cancer is associated with a significant reduction in...
Next Article:Roche Holding AG, the world's biggest maker of tumor drugs, said a late-stage study showed its Herceptin medicine helped slow the spread of breast...
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters